Vilon

Vilon is a synthetic dipeptide bioregulator composed of two amino acids—lysine and glutamic acid (Lys-Glu)—originally derived from thymus tissue extracts. Developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology, Vilon has gained attention for its immunomodulatory properties, potential anti-aging effects, and ability to regulate gene expression at the cellular level. Popular among biohackers, longevity enthusiasts, and individuals seeking immune system support, Vilon is typically administered subcutaneously at doses of 5–10 mg daily for cycles of 5–12 days, repeated every 3–6 months, with users often reporting improvements in immune function and recovery within 2–4 weeks of initiating a cycle.

What Is Vilon?

Vilon, also known as Lysylglutamic Acid or Lysylglutamate, is a short synthetic dipeptide belonging to the class of peptide bioregulators. Its molecular structure consists of just two amino acids—L-lysine and L-glutamic acid—making it one of the smallest bioactive peptides studied for therapeutic potential.<parameter name="url">https://pmc.ncbi.nlm.nih.gov/articles/PMC8999041/</parameter>

The peptide was developed through decades of research by Professor Vladimir Khavinson, who pioneered the field of peptide bioregulation beginning in the 1970s. Khavinson's work demonstrated that short peptides isolated from various organs could exert tissue-specific regulatory effects, and Vilon emerged as a synthetic version of naturally occurring thymic peptides.<parameter name="url">https://link.springer.com/article/10.1134/S2079057014040122</parameter>

What makes Vilon unique among peptides is its remarkably small size combined with significant biological activity. Unlike larger peptide hormones, Vilon can potentially penetrate cellular membranes and interact directly with DNA sequences, specifically binding to the TCGA sequence of double-stranded DNA.<parameter name="url">https://www.mdpi.com/1420-3049/25/19/4389</parameter> This direct gene-regulatory capacity distinguishes it from peptides that work exclusively through cell-surface receptors.

The primary human-use benefits attributed to Vilon include:

 
• Immunomodulation and enhanced T-lymphocyte differentiation
 
• Support for cellular regeneration and tissue repair
 
• Potential anti-aging effects through gene expression modulation
 
• Anti-inflammatory activity
 
• Enhanced wound healing capacity

How It Works

DNA Binding and Gene Expression

Vilon's mechanism of action centers on its ability to interact directly with genetic material. Research has demonstrated that the KE dipeptide can selectively bind to specific DNA sequences, particularly the TCGA nucleotide sequence in double-stranded DNA.<parameter name="url">https://www.mdpi.com/1420-3049/25/19/4389</parameter> This binding capacity allows Vilon to modulate gene expression related to immune cell regulation, proliferation, and differentiation.

Studies have shown that Vilon can increase the expression of interleukin-2 (IL-2) genes in lymphoid cells, a critical cytokine for T-cell proliferation and immune response coordination.<parameter name="url">https://peptidedosages.com/what-is-vilon-2/</parameter>

Immunomodulatory Pathways

At the molecular and cellular level, Vilon's primary immunomodulating effects involve stimulation of thymocyte differentiation into mature T lymphocytes.<parameter name="url">https://www.researchgate.net/publication/236042886_Immunomodulating_Effects_of_Vilon_and_Its_Analogue_in_the_Culture_of_Human_and_Animal_Thymus_Cells</parameter> Research conducted on human and animal thymus cell cultures has demonstrated that Vilon activates T-helper cells through inhibition of cellular apoptosis pathways.

The peptide also influences cytokine signaling, with studies showing reduced expression of pro-inflammatory cytokines including TNF-α, IL-6, and IL-17 when macrophages are treated with Vilon in the presence of inflammatory stimuli.<parameter name="url">https://pmc.ncbi.nlm.nih.gov/articles/PMC8999041/</parameter>

STAT Signaling Activation

Laboratory research has revealed that Vilon can activate STAT1 (Signal Transducer and Activator of Transcription 1) phosphorylation in differentiated macrophages. This activation occurs through a receptor-independent mechanism, meaning the peptide may directly influence intracellular signaling without requiring traditional ligand-receptor interactions.<parameter name="url">https://pmc.ncbi.nlm.nih.gov/articles/PMC8999041/</parameter>

Confocal microscopy studies have confirmed that Vilon treatment promotes the translocation of activated STAT1 molecules from the cytoplasm into cell nuclei, where they can influence gene transcription.

Cellular Proliferation and Regeneration

Vilon has been implicated in regeneration of eye retinal cells and brain neurons, and promotes cell proliferation and wound healing.<parameter name="url">https://pmc.ncbi.nlm.nih.gov/articles/PMC8999041/</parameter> The peptide influences mitogen-activated protein kinase (MAPK) pathways, including ERK1/2 phosphorylation, which plays a central role in cellular proliferation and survival signaling.

Dosage Protocols

Vilon dosing protocols vary based on the intended application, though several common approaches have emerged from research and clinical practice:

Standard Immune Support Protocol:

• Dosage: 5 mg administered subcutaneously once daily
• Duration: 10–12 days per cycle
• Frequency: Repeat every 4–6 months<parameter name="url">https://www.peptides.org/vilon-dosage-calculator/</parameter>

Intensive Protocol:

• Dosage: 10 mg injected once daily
• Duration: 5–10 days per month
• Frequency: Every 3–6 months<parameter name="url">https://jaycampbell.com/peptides/vilon-benefits/</parameter>

Bioregulator Cycling Approach:
As with other peptide bioregulators, Vilon is typically cycled rather than used continuously. The rationale behind cycling involves allowing the body's natural regulatory systems to respond to the peptide's effects while preventing potential receptor desensitization. Most protocols recommend 2–4 cycles per year, with each cycle lasting 10–12 days.

How to Use / Administration

Vilon is most commonly administered via subcutaneous (SC) injection, though intramuscular (IM) injection is also utilized. The subcutaneous route is preferred for its ease of self-administration and consistent absorption profile.

Injection Sites:

• Abdominal area (2 inches from navel)
• Upper outer thigh
• Back of upper arm

Administration Steps:

1. Reconstitute lyophilized powder with bacteriostatic water
2. Allow solution to dissolve completely without shaking
3. Draw appropriate dose into insulin syringe
4. Clean injection site with alcohol swab
5. Pinch skin and inject at 45-degree angle
6. Rotate injection sites to prevent tissue irritation

Vilon is also available in oral capsule form in some markets, though injectable administration is considered more bioavailable for this peptide class.

Results Timelines

Users and researchers report varying timelines for observing effects from Vilon administration:

Week 1–2: Initial immune system modulation may begin, though effects are typically subtle. Some users report improved energy levels and general well-being.

Week 2–4: More noticeable improvements in immune function, including reduced frequency of minor infections and faster recovery from illness. Enhanced wound healing may become apparent.

Week 4–8: Cumulative effects on cellular regeneration and tissue repair become more evident. Users focused on anti-aging applications may notice improvements in skin quality and recovery capacity.

Long-term (3–6 months post-cycle): The bioregulatory effects of Vilon are designed to persist beyond the active administration period. Many users report sustained immune benefits for several months following a cycle, which is consistent with the peptide's gene-regulatory mechanism of action.

Research Evidence

The scientific literature on Vilon spans several decades, with much of the foundational research conducted at Russian institutions under Professor Khavinson's direction.

A 2022 study published in the International Journal of Molecular Sciences evaluated Vilon alongside other Khavinson peptides on human monocytic THP-1 cells. The research demonstrated that Vilon could modulate proliferative patterns, influence STAT1 phosphorylation, and reduce pro-inflammatory cytokine release when cells were exposed to bacterial lipopolysaccharide (LPS).<parameter name="url">https://pmc.ncbi.nlm.nih.gov/articles/PMC8999041/</parameter>

Research published in the Bulletin of Experimental Biology and Medicine examined Vilon's immunomodulating effects in human and animal thymus cell cultures, confirming its ability to stimulate thymocyte differentiation and T-lymphocyte activation.<parameter name="url">https://www.researchgate.net/publication/236042886_Immunomodulating_Effects_of_Vilon_and_Its_Analogue_in_the_Culture_of_Human_and_Animal_Thymus_Cells</parameter>

Long-term animal studies have investigated Vilon's effects on lifespan and tumor development. Research on mice demonstrated that Vilon administration could inhibit spontaneous tumor growth and increase lifespan, with injections at 1 mg/kg showing significant survival benefits.<parameter name="url">https://pubmed.ncbi.nlm.nih.gov/14743610/</parameter>

A comprehensive review of peptide bioregulators as geroprotectors summarized clinical efficacy data for Vilon and related compounds, noting their potential for preventing age-related immune decline.<parameter name="url">https://link.springer.com/article/10.1134/S2079057014040122</parameter>

Stacking

Vilon is frequently combined with other peptide bioregulators to create synergistic protocols targeting specific health goals:

Immune Enhancement Stack:
Vilon + Thymalin + Thymogen represents a comprehensive thymus-derived peptide combination. All three peptides possess complementary immunomodulatory mechanisms, with Thymalin providing a broader peptide complex while Vilon and Thymogen offer more targeted dipeptide activity.<parameter name="url">https://jaycampbell.com/peptides/vilon-benefits/</parameter>

Anti-Aging Protocol:
Vilon + Epitalon combines immune support with pineal gland regulation. Epitalon (Ala-Glu-Asp-Gly) has been studied for its effects on telomerase activation and melatonin synthesis, complementing Vilon's immune-regulatory properties.

Tissue Regeneration Stack:
Vilon + BPC-157 or TB-500 may be combined for enhanced tissue repair applications, though users should research potential interactions and consult healthcare providers before combining multiple peptides.

When stacking, peptides are typically administered at separate injection sites or at different times of day to ensure optimal absorption and minimize potential interactions.

Reconstitution, Storage & Prep

Vilon is supplied as a lyophilized (freeze-dried) powder to maintain stability and purity. Proper reconstitution and storage are essential for preserving peptide integrity.

Reconstitution Protocol:

1. Allow vial to reach room temperature before reconstitution
2. Use bacteriostatic water (BAC water) as the reconstitution solvent
3. For a 20 mg vial, add 2 mL of BAC water for a concentration of 10 mg/mL
4. Direct the water stream against the vial wall, not directly onto the powder
5. Allow the powder to dissolve naturally; do not shake or vortex
6. Gently swirl if needed to complete dissolution

Storage Guidelines:

• Lyophilized (unreconstituted): Store frozen at −20°C (−4°F) for long-term stability
• Reconstituted solution: Refrigerate at 2–8°C (35.6–46.4°F)
• Use reconstituted peptide within 1 week, or aliquot and freeze for extended storage
• Protect from light and avoid repeated freeze-thaw cycles<parameter name="url">https://peptidedosages.com/single-peptide-dosages/vilon-20mg-vial-dosage-protocol/</parameter>

Side Effects

Vilon is generally considered well-tolerated with a favorable safety profile based on available research. Long-term mouse studies reported no adverse developmental effects from Vilon administration.<parameter name="url">https://jaycampbell.com/peptides/vilon-benefits/</parameter>

Reported Side Effects (Mild and Infrequent):

• Injection site reactions (redness, mild swelling, itching)
• Mild headaches
• Digestive upset
• Temporary fatigue during initial administration<parameter name="url">https://scaleregenerativehealth.com/bioregulators/vilon</parameter>

Related thymic peptides (Thymalin, Thymogen) have been noted to have practically no side effects in clinical use for various viral infections.<parameter name="url">https://pmc.ncbi.nlm.nih.gov/articles/PMC8365293/</parameter>

Precautions:
Individuals with autoimmune conditions should exercise caution, as immunomodulatory peptides may theoretically influence autoimmune processes. Those with active cancer, pregnant or breastfeeding women, and individuals with significant kidney or liver disease should consult healthcare providers before use.

Legal Status / FDA

Vilon is not approved by the U.S. Food and Drug Administration (FDA) for any medical indication. In the United States, it is classified as a research chemical and is legally sold for research purposes only, not for human consumption.

In Russia and some Eastern European countries, peptide bioregulators including Vilon have been used in clinical practice and are available as dietary supplements or pharmaceutical preparations. Thymalin and Thymogen, related thymic peptides, have been approved for clinical use in Russia for immunodeficiency conditions.<parameter name="url">https://pmc.ncbi.nlm.nih.gov/articles/PMC8999041/</parameter>

The regulatory status varies significantly by country, and individuals should verify local laws before purchasing or using Vilon.

Sports / WADA

While Vilon is not specifically named on the World Anti-Doping Agency (WADA) Prohibited List, athletes should exercise caution. WADA's prohibited list includes broad categories of peptide hormones and growth factors under section S2, and the agency maintains the authority to prohibit substances with similar biological effects to those explicitly listed.<parameter name="url">https://www.wada-ama.org/en/prohibited-list</parameter>

Peptide molecules are found in official WADA lists, mainly in sections S2, S4, and S5, and WADA has developed screening protocols capable of detecting peptides under 2 kDa.<parameter name="url">https://pmc.ncbi.nlm.nih.gov/articles/PMC9631397/</parameter>

Athletes subject to anti-doping testing should consult with their sport's governing body and anti-doping authority before using any peptide compound, including Vilon.

Conclusion

Vilon represents a fascinating example of how minimalist molecular structures can exert significant biological effects. As a dipeptide consisting of just two amino acids, its ability to modulate gene expression, influence immune function, and potentially support cellular regeneration challenges conventional assumptions about the relationship between molecular size and biological activity.

The research foundation for Vilon, while substantial in certain contexts, remains limited by the lack of large-scale, placebo-controlled human clinical trials meeting Western regulatory standards. Most evidence derives from cell culture studies, animal models, and clinical observations from Russian research institutions.

For individuals considering Vilon, the peptide offers a relatively well-tolerated option for immune support and potential anti-aging applications. Its cycling protocol aligns with the bioregulator philosophy of periodic intervention rather than continuous supplementation, and its compatibility with other peptides makes it a versatile component of comprehensive wellness protocols.

As with all non-approved peptides, users should approach Vilon with appropriate caution, source from reputable suppliers, and ideally work with healthcare providers knowledgeable about peptide therapeutics.

FAQ

What is Vilon peptide used for?
Vilon is primarily used for immune system support, cellular regeneration, and potential anti-aging applications. Research suggests it may enhance T-lymphocyte differentiation, reduce inflammation, and support tissue repair processes.

How long does it take for Vilon to work?
Initial effects may be noticed within 1–2 weeks, with more substantial immune and regenerative benefits typically observed after 2–4 weeks. The bioregulatory effects are designed to persist for several months following a cycle.

Is Vilon safe?
Preclinical data and clinical observations suggest a favorable safety profile with no serious adverse effects reported. However, Vilon is not FDA-approved, and long-term human safety data from controlled trials is limited.

How is Vilon different from Thymalin or Thymogen?
While all three are thymus-derived peptide bioregulators, Vilon (Lys-Glu) is a synthetic dipeptide, Thymogen (Glu-Trp) is also a dipeptide but with different amino acids, and Thymalin is a natural peptide complex extracted from calf thymus containing multiple peptide fractions.

Can Vilon be taken orally?
Vilon is available in oral capsule form in some markets, though subcutaneous injection is considered the preferred route for optimal bioavailability. Oral bioregulator formulations may have reduced absorption compared to injectable forms.

How often should Vilon cycles be repeated?
Most protocols recommend 2–4 cycles per year, with each cycle lasting 10–12 days. Cycles are typically spaced 3–6 months apart to allow the body's regulatory systems to respond to the peptide's effects.

Can Vilon be stacked with other peptides?
Yes, Vilon is commonly combined with other bioregulator peptides such as Thymalin, Thymogen, and Epitalon for synergistic effects. When stacking, peptides should be administered at separate sites or times.

Is Vilon legal to purchase?
In the United States, Vilon is legal to purchase for research purposes but is not approved for human use. Regulatory status varies by country, and individuals should verify local laws before purchasing.

References

1. Avolio F, et al. "Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line." International Journal of Molecular Sciences. 2022;23(7):3607. https://pmc.ncbi.nlm.nih.gov/articles/PMC8999041/
2. Khavinson VK, et al. "Peptide bioregulators: A new class of geroprotectors, Report 2." Advances in Gerontology. 2014. https://link.springer.com/article/10.1134/S2079057014040122
3. Sevostianova NN, et al. "Immunomodulating Effects of Vilon and Its Analogue in the Culture of Human and Animal Thymus Cells." Bulletin of Experimental Biology and Medicine. 2013;154:562-565. https://www.researchgate.net/publication/236042886_Immunomodulating_Effects_of_Vilon_and_Its_Analogue_in_the_Culture_of_Human_and_Animal_Thymus_Cells
4. Khavinson V, et al. "Peptides: Prospects for Use in the Treatment of COVID-19." Molecules. 2020;25(19):4389. https://www.mdpi.com/1420-3049/25/19/4389
5. Kuznik BI, et al. "The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity of Thymic Peptides." International Journal of Molecular Sciences. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8365293/
6. Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology. 2010. https://www.semanticscholar.org/paper/Peptide-bioregulation-of-aging%3A-results-and-Anisimov-Khavinson/a68baf4144e88b5c8265941cf01cc4f3127bc01d
7. Khavinson VK, Popovich IG. "Short Peptides Regulate Gene Expression, Protein Synthesis and Modulate Cell Activity." 2017. https://khavinson.info/assets/files/skan/2017-khavinson_popovich.pdf
8. World Anti-Doping Agency. "The Prohibited List." 2026. https://www.wada-ama.org/en/prohibited-list
9. Morozov VG, Khavinson VK. "Natural and synthetic thymic peptides as therapeutics for immune dysfunction." International Journal of Immunopharmacology. 1997;19:501-505. https://www.sciencedirect.com/science/article/pii/S0192056197000581
10. Linkova NS, et al. "Age-related molecular aspects of immunomodulating activity of short peptides." Advances in Gerontology. 2014. https://link.springer.com/article/10.1134/S2079057014010020